Ken Griffin Citadel Advisors
Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$772M |
| 2 |
Eli Lilly
LLY
|
+$337M |
| 3 |
lululemon athletica
LULU
|
+$301M |
| 4 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$297M |
| 5 |
ResMed
RMD
|
+$273M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$576M |
| 2 |
AT&T
T
|
+$476M |
| 3 |
PNC Financial Services
PNC
|
+$393M |
| 4 |
Fortive
FTV
|
+$389M |
| 5 |
Accenture
ACN
|
+$374M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 2.83% |
| 2 | Technology | 2.79% |
| 3 | Financials | 2.29% |
| 4 | Consumer Discretionary | 1.93% |
| 5 | Industrials | 1.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
6651
RLX Technology
RLX
$2.2B
| $1.13M | ﹤0.01% |
530,152
-982,702
| -65% | -$1.98M |
|
6652
CALL
Amphenol
APH
$197B
| $1.13M | ﹤0.01% |
35,000
-1,200
| -3% | -$41.7K |
|
6653
PUT
Beam Global
BEEM
$24.2M
| $1.13M | ﹤0.01% |
72,600
-32,800
| -31% | -$565K |
|
|
EAOM
6654
DELISTED
iShares ESG Aware Moderate Allocation ETF
EAOM
| $1.13M | ﹤0.01% |
45,334
+6,110
| +16% | +$157K |
|
6655
PUT
Northern Oil and Gas
NOG
$2.71B
| $1.13M | ﹤0.01% |
44,600
-62,600
| -58% | -$1.82M |
|
6656
CALL
Saic
SAIC
$5.34B
| $1.13M | ﹤0.01% |
12,100
-12,100
| -50% | -$1.06M |
|
|
CSA
6657
DELISTED
VictoryShares US Small Cap Volatility Wtd ETF
CSA
| $1.13M | ﹤0.01% |
19,950
+531
| +3% | +$31.6K |
|
6658
CALL
Ginkgo Bioworks
DNA
$446M
| $1.12M | ﹤0.01% |
11,810
-1,833
| -13% | -$224K |
|
6659
PUT
Perrigo
PRGO
$1.82B
| $1.12M | ﹤0.01% |
27,700
-8,800
| -24% | -$327K |
|
6660
Alnylam Pharmaceuticals
ALNY
$30.4B
| $1.12M | ﹤0.01% |
7,694
+5,586
| +265% | +$792K |
|
6661
Ambarella
AMBA
$3.31B
| $1.12M | ﹤0.01% |
17,154
-97,449
| -85% | -$7.85M |
|
6662
PUT
HealthEquity
HQY
$8.67B
| $1.12M | ﹤0.01% |
18,300
-23,100
| -56% | -$1.48M |
|
6663
PUT
Sylvamo
SLVM
$1.47B
| $1.12M | ﹤0.01% |
34,360
-34,693
| -50% | -$1.45M |
|
6664
The RealReal
REAL
$1.35B
| $1.12M | ﹤0.01% |
450,733
+163,035
| +57% | +$726K |
|
6665
PIMCO Investment Grade Corporate Bond Index Exchange-Traded Fund
CORP
$1.59B
| $1.12M | ﹤0.01% |
11,635
-159,118
| -93% | -$15.7M |
|
6666
PUT
Zevra Therapeutics
ZVRA
$682M
| $1.12M | ﹤0.01% |
251,200
-1,700
| -0.7% | -$7.75K |
|
|
DNMR
6667
CALL
DELISTED
Danimer Scientific, Inc.
DNMR
| $1.12M | ﹤0.01% |
6,140
-3,270
| -35% | -$594K |
|
6668
Distillate International Fundamental Stability & Value ETF
DSTX
$71M
| $1.12M | ﹤0.01% |
53,545
-4,222
| -7% | -$95K |
|
6669
CALL
Hercules Capital
HTGC
$3.1B
| $1.12M | ﹤0.01% |
82,900
+57,800
| +230% | +$903K |
|
6670
PUT
First Trust NASDAQ Clean Edge Green Energy Index Fund
QCLN
$594M
| $1.12M | ﹤0.01% |
21,400
-3,000
| -12% | -$164K |
|
6671
Groupon
GRPN
$836M
| $1.12M | ﹤0.01% |
98,818
-76,605
| -44% | -$1.26M |
|
6672
CALL
Lennox International
LII
$14.2B
| $1.12M | ﹤0.01% |
5,400
-100
| -2% | -$21.9K |
|
6673
Patria Investments
PAX
$1.83B
| $1.12M | ﹤0.01% |
84,451
-56,629
| -40% | -$893K |
|
6674
CALL
Coca-Cola Europacific Partners
CCEP
$47.7B
| $1.11M | ﹤0.01% |
21,600
-9,600
| -31% | -$491K |
|
6675
CALL
Monarch Casino & Resort
MCRI
$2.21B
| $1.11M | ﹤0.01% |
19,000
-12,700
| -40% | -$891K |
|
Similar funds
Ken Griffin's Q2 2022 Portfolio in Review
As of Q2 2022, Ken Griffin held 14,957 positions worth $390B, down 20% from $484B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Ken Griffin's Q2 2022 filing shows 1,520 new, 5,503 increased, 5,522 reduced and 2,191 closed positions. Its largest new stake was ResMed: 1,280,595 shares worth $268M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $576M.
By sector, the portfolio is most concentrated in Healthcare at 2.8% of assets, up from 2.4% a quarter earlier, followed by Technology and Financials.
- Ken Griffin's largest Q2 2022 buy was ResMed: 1,280,595 shares worth $268M.
- Ken Griffin added most to Meta Platforms (Facebook) in Q2 2022, an estimated $772M increase.
- Ken Griffin's biggest Q2 2022 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $576M.
- Ken Griffin fully exited Vanguard Morningstar Small-Cap ETF in Q2 2022, selling an estimated $184M.
- Ken Griffin's ten largest holdings make up 28% of its $390B portfolio in Q2 2022.
- Ken Griffin opened 1,520 new positions and closed 2,191 in Q2 2022.
- Ken Griffin's portfolio value fell 20% quarter-over-quarter to $390B.
Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.